TherapeuticsMD (TXMD) Change in Accured Expenses (2010 - 2026)

TherapeuticsMD (TXMD) has reported Change in Accured Expenses for 17 consecutive years, with -$363000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 91.05% year-over-year to -$363000.0; the trailing twelve-month figure through Jun 2026 stood at $259000.0 (up 155.7% YoY), and the FY2025 full-year result was $272000.0, up 127.04% from the prior year.
• Change in Accured Expenses eased to -$363000.0 in Q2 2026 per TXMD's latest filing, from $434000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $19.1 million in Q3 2022 and bottomed at -$14.1 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$673000.0 across 5 years, with a median of -$300000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses jumped 3282.27% in 2022, then tumbled 331.82% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$14.1 million in 2022, then soared by 73.04% to -$3.8 million in 2023, then soared by 81.79% to -$691000.0 in 2024, then jumped by 65.7% to -$237000.0 in 2025, then slumped by 53.16% to -$363000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$363000.0, $434000.0, and -$237000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.